Chylothorax: A Comprehensive Review

Introduction

Chylothorax is an uncommon but clinically significant pleural effusion characterised by the accumulation of chyle within the pleural space. Chyle is a lymphatic fluid rich in triglycerides, formed during the absorption of dietary fats from the intestines and transported via the thoracic duct to the venous system.

The presence of chyle in the pleural cavity can result in considerable morbidity due to respiratory compromise, nutritional loss, and immune suppression. Chylothorax may arise from various causes, including traumatic injury to the thoracic duct, malignancy, and congenital abnormalities.

Epidemiologically, chylothorax is rare, with an incidence estimated at 1 in 20,000 hospital admissions. It is reported more frequently in paediatric populations, especially neonates and infants, due to congenital causes. In adults, chylothorax is often associated with trauma, surgical procedures, or malignancies. The disease can occur in both genders and across all age groups, although certain causes have age and demographic predilections.

Definition and Pathophysiology

Definition

Chylothorax is defined as the presence of chyle within the pleural cavity. Chyle is a milky, opalescent fluid composed of lymph, emulsified fats (chylomicrons), electrolytes, immunoglobulins, and lymphocytes. The diagnosis is confirmed by pleural fluid analysis revealing elevated triglyceride concentrations (typically >110 mg/dL), the presence of chylomicrons, and a characteristic milky appearance.

Pathophysiology

The pathogenesis of chylothorax involves disruption of the thoracic duct or its tributaries, leading to leakage of chyle into the pleural space. The thoracic duct is the principal lymphatic channel draining lymph from the abdomen, pelvis, lower limbs, and left side of the thorax, head, and neck into the venous circulation at the junction of the left subclavian and internal jugular veins. Injury or obstruction to the thoracic duct can result in chyle extravasation. The rate and volume of chyle loss depend on the site and extent of ductal disruption, underlying disease process, and lymphatic pressure.

The accumulation of chyle in the pleural cavity leads to several physiological consequences:

• Respiratory compromise due to lung compression and reduced ventilation
• Loss of proteins, fats, fat-soluble vitamins, electrolytes, and lymphocytes, resulting in malnutrition and immunodeficiency
• Chronic pleural inflammation and fibrosis in prolonged cases

Etiology

Chylothorax can be classified based on its underlying cause as primary (idiopathic or congenital) or secondary (acquired).

Primary (Congenital) Causes

• Congenital lymphatic malformations: Abnormal development of lymphatic vessels, including lymphangiomatosis, may lead to spontaneous chyle leakage.
• Genetic syndromes: Conditions such as Noonan syndrome, Turner syndrome, and Down syndrome have been associated with congenital chylothorax.
• Idiopathic: In some cases, no identifiable cause is found despite thorough investigation.

Secondary (Acquired) Causes

• Traumatic injury: Blunt or penetrating trauma to the thorax, or iatrogenic injury during surgical procedures (e.g., oesophagectomy, thoracic aortic repair, mediastinal lymph node dissection).
• Malignancy: Lymphoma is the most common malignant cause, followed by other cancers such as bronchogenic carcinoma, metastatic disease, and leukaemia. Tumour infiltration or compression of the thoracic duct impairs lymphatic drainage.
• Infectious diseases: Tuberculosis, filariasis, and other infections may result in lymphatic obstruction or rupture.
• Miscellaneous conditions: Superior vena cava thrombosis, sarcoidosis, amyloidosis, and radiation therapy can also precipitate chylothorax.

Clinical Presentation

Signs and Symptoms

The clinical manifestations of chylothorax vary depending on the rate of chyle accumulation, underlying aetiology, and patient demographics. Common symptoms include:

• Dyspnoea: Progressive shortness of breath due to pleural fluid accumulation and lung compression.
• Chest pain: Generally non-specific and may be pleuritic in nature.
• Cough: Often dry and persistent.
• Systemic features: Fatigue, weight loss, and malnutrition due to ongoing protein and fat loss.
• Immunosuppression: Increased susceptibility to infections as a result of lymphocyte depletion.

Physical examination may reveal decreased breath sounds, dullness to percussion, reduced chest expansion, and, in severe cases, signs of respiratory distress. In infants and neonates, chylothorax may present with tachypnoea, cyanosis, feeding difficulties, and failure to thrive.

Patient Demographics

Chylothorax affects both adults and children. In paediatric populations, congenital and idiopathic causes predominate, whereas in adults, trauma, surgery, and malignancy are more frequent. There is no significant gender predilection, although some congenital syndromes may have gender associations. The timing of presentation often correlates with the underlying cause; for example, post-surgical chylothorax typically manifests within days to weeks following thoracic procedures.

Diagnostic Approach

Imaging Modalities

Imaging plays a vital role in the evaluation of chylothorax:

• Chest X-ray: Reveals pleural effusion but cannot differentiate chylothorax from other fluid types.
• Ultrasound: Useful for quantifying pleural fluid and guiding thoracentesis.
• Computed Tomography (CT): Provides detailed assessment of the pleural cavity, mediastinal structures, and potential underlying malignancy or lymphatic obstruction.
• Magnetic Resonance Imaging (MRI): Offers superior soft tissue contrast and may delineate lymphatic anatomy and pathology.
• Lymphangiography: Direct visualisation of the lymphatic system, useful in localising the site of leak and planning surgical intervention.
• Indocyanine green (ICG) lymphography: Emerging technique for real-time mapping of lymphatic flow.

Laboratory Tests

Laboratory analysis of pleural fluid is essential for diagnosis:

• Appearance: Chylous fluid is typically milky and opalescent.
• Triglyceride level: >110 mg/dL is diagnostic; levels below this may require further evaluation.
• Chylomicrons: Presence confirmed by lipoprotein electrophoresis.
• Cell count: Lymphocyte predominance is characteristic.
• Protein content: Generally high, reflecting loss of plasma proteins.
• Other tests: Microbiological studies to rule out infection, cytology for malignancy, and biochemical analysis for differential diagnosis.

Differential Diagnosis

Several conditions may mimic chylothorax and must be differentiated:

• Pseudochylothorax: Chronic pleural effusion with cholesterol-rich fluid, usually secondary to tuberculosis or rheumatoid disease. Distinguished by lower triglyceride levels and absence of chylomicrons.
• Empyema: Purulent pleural fluid due to infection; fluid is turbid and foul-smelling, with elevated white cell count.
• Malignant pleural effusion: May resemble chylothorax, especially in cases of lymphatic obstruction.
• Other exudative effusions: Heart failure, hepatic hydrothorax, nephrotic syndrome, and other causes.

Management Strategies

The treatment of chylothorax aims to control pleural effusion, restore nutrition, treat the underlying cause, and prevent complications. Management can be broadly categorised as conservative, interventional, or surgical.

Conservative Management

• Dietary modification: Instituting a low-fat diet with medium-chain triglycerides (MCTs) reduces chyle flow, as MCTs are absorbed directly into the portal circulation. In severe cases, total parenteral nutrition (TPN) may be necessary.
• Serial thoracentesis: Therapeutic removal of pleural fluid can alleviate symptoms and respiratory compromise.
• Octreotide therapy: A somatostatin analogue, octreotide reduces lymphatic flow and has shown variable efficacy in chylothorax.
• Supportive care: Includes fluid and electrolyte replacement, nutritional support, and infection prevention.

Interventional Management

• Pleurodesis: Chemical or mechanical pleurodesis induces pleural adhesion, preventing reaccumulation of chyle. Agents such as talc, doxycycline, or bleomycin may be used.
• Pleural drainage: Placement of an indwelling pleural catheter or chest tube for ongoing fluid removal.
• Image-guided interventions: Lymphangiography-guided embolisation of the thoracic duct is an emerging minimally invasive technique.

Surgical Management

• Thoracic duct ligation: Surgical ligation of the duct is indicated in refractory cases or when the site of leak is localised.
• Pleurectomy: Removal of the pleural lining may be considered in chronic or recurrent effusions.
• Thoracic duct repair or anastomosis: In selected cases, direct repair or bypass of the duct may be feasible.
• Thoracoscopic approaches: Video-assisted thoracoscopic surgery (VATS) offers a minimally invasive option for duct ligation and pleurodesis.

The choice of therapy depends on the severity of effusion, underlying aetiology, patient comorbidities, and response to initial treatment. Multidisciplinary management involving pulmonologists, thoracic surgeons, dietitians, and interventional radiologists is often required.

Complications and Prognosis

Complications

Untreated or recurrent chylothorax may lead to several complications:

• Malnutrition: Loss of proteins, fats, and vitamins impairs growth and recovery.
• Immunosuppression: Lymphocyte depletion increases risk of infections.
• Electrolyte disturbances: Loss of sodium, potassium, calcium, and other electrolytes.
• Respiratory failure: Large effusions may cause hypoxaemia and respiratory distress.
• Pleural fibrosis: Chronic inflammation may lead to restrictive lung disease.

Prognosis

The outcome in chylothorax varies with the underlying cause, patient age, and response to treatment. Idiopathic and traumatic chylothorax generally have favourable outcomes with conservative or surgical management. Malignant chylothorax, especially due to lymphoma or metastatic disease, carries a poorer prognosis due to the advanced nature of underlying pathology.

Prompt diagnosis and appropriate intervention are critical to prevent complications. Paediatric patients, particularly neonates, require special attention due to their vulnerability to nutritional and immune deficits. Long-term follow-up is recommended to monitor for recurrence, nutritional status, and respiratory function.

Nursing Care of Patients with Chylothorax

The role of the nurse is pivotal in identifying, monitoring, and holistically managing patients with chylothorax to optimize outcomes and minimize complications.

Assessment and Diagnosis

Nurses play a crucial role in the early identification and ongoing assessment of chylothorax. Key components include:

• History-taking: Assess recent surgeries, trauma, malignancy, or symptoms suggestive of lymphatic obstruction.
• Physical assessment: Look for signs of respiratory distress—tachypnea, dyspnea, decreased breath sounds, and dullness to percussion over the affected side. Assess for malnutrition, edema, and signs of infection.
• Monitoring output: If a chest drain is in situ, document the volume and appearance of pleural fluid. Chyle typically appears milky, especially after the patient eats.
• Laboratory support: Assist with obtaining and sending pleural fluid samples for triglyceride levels, cell counts, and cultures. Chylous fluid usually has a triglyceride concentration >110 mg/dL.

Nursing Diagnoses

Potential nursing diagnoses for patients with chylothorax may include:

• Ineffective breathing pattern related to pleural fluid accumulation
• Impaired gas exchange due to compromised lung expansion
• Imbalanced nutrition: less than body requirements, related to loss of chyle
• Risk of infection related to loss of immunoglobulins and lymphocytes
• Risk for fluid volume deficit due to continuous chyle drainage
• Anxiety related to health condition and hospital environment

Goals of Nursing Care

• Promote optimal respiratory function and comfort
• Prevent or detect complications early, such as infection or malnutrition
• Maintain adequate nutritional and fluid status
• Provide emotional support and education to the patient and family

Interventions

1. Respiratory Support and Monitoring

• Monitor respiratory rate, effort, and oxygen saturation vigilantly.
• Assess breath sounds regularly and document changes.
• Encourage deep breathing and coughing exercises to improve lung expansion.
• Provide supplemental oxygen as prescribed to maintain SpO2 above 92%.
• Assist in positioning (e.g., semi-Fowler’s) to enhance ventilation and comfort.
• Observe for signs of respiratory distress or compromise and notify the physician promptly.

2. Chest Drain Management

• Ensure the chest drainage system is intact, properly positioned, and functioning.
• Monitor and record the volume, color, and consistency of drainage frequently.
• Maintain a sterile field when handling drainage systems to prevent infection.
• Secure the drain site, monitor for leaks, and change dressings as per protocol.
• Educate the patient and family about the purpose and care of the chest tube.

3. Nutritional Management

• Collaborate with a dietitian to plan appropriate nutritional support.
• Encourage a high-protein, low-fat diet with medium-chain triglycerides (MCTs), as MCTs are absorbed directly into the portal system, bypassing the lymphatics.
• If oral intake is insufficient or contraindicated, anticipate the need for enteral or parenteral nutrition.
• Monitor weight, serum albumin, and electrolyte levels to assess nutritional status.
• Educate the patient and family about dietary modifications and the importance of adherence.

4. Fluid and Electrolyte Balance

• Monitor intake and output meticulously, including chest drain output.
• Assess for signs of dehydration: dry mucous membranes, decreased skin turgor, hypotension, tachycardia.
• Monitor electrolyte levels and replace deficits as prescribed (e.g., sodium, potassium, calcium, magnesium).
• Administer intravenous fluids as ordered, especially if large volumes of chyle are lost.

5. Infection Prevention

• Maintain strict aseptic technique during invasive procedures and dressing changes.
• Monitor for signs of local or systemic infection: fever, increased WBC count, redness or purulent discharge at insertion sites.
• Educate the patient about signs of infection and when to seek help.
• Ensure the patient receives appropriate immunizations, especially if lymphocyte count is low.

6. Psychological and Emotional Support

• Provide reassurance and information about the condition, procedures, and expected outcomes.
• Encourage questions and active participation in care decisions.
• Support family involvement and address their concerns empathetically.
• Refer to counseling or social work services if anxiety or stress is significant.

7. Patient and Family Education

• Explain the nature of chylothorax, its causes, and management strategies.
• Teach chest tube care and signs of complications if discharge with the tube is anticipated.
• Instruct on dietary modifications and the importance of follow-up laboratory testing.
• Promote awareness about the importance of medication adherence and follow-up appointments.

Monitoring and Evaluation

Ongoing evaluation is essential to ensure the effectiveness of interventions and to detect complications early. Monitor the patient for:

• Improvement in respiratory status (decreased work of breathing, improved oxygenation)
• Reduction or cessation of chyle output
• Stabilization of nutritional and fluid parameters
• Absence of infection or prompt management if detected
• Psychological well-being and adjustment to the care plan

Document findings meticulously and communicate any concerns promptly to the interdisciplinary team.

Complications and Their Management

Chylothorax can lead to several complications, including:

• Respiratory compromise or failure
• Severe malnutrition and weight loss
• Electrolyte imbalances
• Immunosuppression (due to loss of lymphocytes and immunoglobulins)
• Infection (especially pneumonia or sepsis)
• Persistent or recurrent chylothorax requiring surgical intervention

Timely recognition and intervention for each complication are vital. Nurses should be vigilant for sudden changes in condition and advocate for prompt medical or surgical management as needed.

Collaborative Care

Nurses are integral members of a multidisciplinary team, which may include physicians, dietitians, respiratory therapists, pharmacists, and social workers. Collaborative care focuses on:

• Deciding between conservative (dietary and drainage) versus surgical management
• Providing tailored nutrition and fluid support
• Ensuring optimal respiratory care
• Supporting the patient’s psychosocial needs
• Planning for discharge and follow-up

Discharge Planning and Home Care

Planning for discharge starts early. Nurses help prepare patients and families by:

• Reinforcing education on dietary modifications and medication regimens
• Teaching chest tube management, if applicable
• Arranging for home health services as appropriate
• Coordinating follow-up appointments and ongoing laboratory monitoring
• Providing information on signs of complications and when to seek immediate care

REFERENCES

1. Attar MA, Donn SM. Congenital chylothorax. https://pubmed.ncbi.nlm.nih.gov/28351595/) Semin Fetal Neonatal Med. 2017 Aug;22(4):234-239.
2. Jackson S, Jnah AJ. Chylothorax: A Stepwise Approach to Diagnosis and Treatment. Neonatal Netw. 2021 Nov 1;40(6):386-392. doi: 10.1891/11-T-705. PMID: 34845089.
3. Light RW. Disorders of the Pleura. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J, eds. Harrison’s Principles of Internal Medicine. 21st ed. McGraw Hill; 2022.
4. Bhatnagar M, Fisher A, Ramsaroop S, Carter A, Pippard B. Chylothorax: pathophysiology, diagnosis, and management-a comprehensive review. J Thorac Dis. 2024 Feb 29;16(2):1645-1661.
5. McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options., https://pubmed.ncbi.nlm.nih.gov/19766473/. Respir Med. 2010 Jan;104(1):1-8.
6. Schild HH, Strassburg CP, Welz A, Kalff J. Treatment options in patients with chylothorax. https://pubmed.ncbi.nlm.nih.gov/24333368/. Dtsch Arztebl Int. 2013 Nov 29;110(48):819-26.
7. Ur Rehman K, Sivakumar P. Non-traumatic chylothorax: diagnostic and therapeutic strategies. Breathe (Sheff). 2022 Jun;18(2):210163.

Stories are the threads that bind us; through them, we understand each other, grow, and heal.

JOHN NOORD

Connect with “Nurses Lab Editorial Team”

I hope you found this information helpful. Do you have any questions or comments? Kindly write in comments section. Subscribe the Blog with your email so you can stay updated on upcoming events and the latest articles.